Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 80Years
All Genders
NCT07010159

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

Led by Kiniksa Pharmaceuticals International, plc · Updated on 2026-05-04

165

Participants Needed

52

Research Sites

231 weeks

Total Duration

On this page

Sponsors

K

Kiniksa Pharmaceuticals International, plc

Lead Sponsor

K

Kiniksa Pharmaceuticals, GmbH

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.

CONDITIONS

Official Title

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of recurrent pericarditis
  • Signs and symptoms of recurrent pericarditis despite standard therapies
  • Weighs at least 40 kg
  • Phase 2: Taking NSAIDs and/or colchicine in any combination
  • Phase 3: Taking NSAIDs and/or colchicine and/or glucocorticoids in any combination
Not Eligible

You will not qualify if you...

  • Pericarditis secondary to specific prohibited causes
  • Received or planning to receive an investigational drug within 4 weeks before or during the study
  • History of active or untreated, latent tuberculosis prior to screening
  • History of immunodeficiency
  • History of immunosuppression including positive HIV test
  • Chest x-ray showing malignancy or infection consistent with TB or active infection within 12 weeks before first study drug
  • History of malignancy within past 5 years except certain treated skin or cervical cancers
  • Known or suspected current active infection or history of chronic/recurrent infections (>3 episodes in prior 12 months)
  • Serious infection requiring hospitalization or antibiotics within 2 weeks prior to first study drug
  • History of organ transplant except corneal transplant over 3 months before first study drug
  • Any other medical condition that could affect participation or study evaluations as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 52 locations

1

Investigational Site 018

Gilbert, Arizona, United States, 85297

Actively Recruiting

2

Investigational Site 030

Los Angeles, California, United States, 90048

Actively Recruiting

3

Investigational Site 008

San Francisco, California, United States, 94158

Actively Recruiting

4

Investigational Site 044

Santa Monica, California, United States, 90404

Actively Recruiting

5

Investigational Site 016

Westminster, Colorado, United States, 80023

Actively Recruiting

6

Investigational Site 001

Columbus, Georgia, United States, 31904

Withdrawn

7

Investigational Site 004

Chicago, Illinois, United States, 60611

Actively Recruiting

8

Investigational Site 014

Indianapolis, Indiana, United States, 46184

Actively Recruiting

9

Investigational Site 002

Overland Park, Kansas, United States, 66221

Withdrawn

10

Investigational Site 043

Baltimore, Maryland, United States, 21287

Actively Recruiting

11

Investigational Site 012

Rochester, Minnesota, United States, 55905

Actively Recruiting

12

Investigational Site 050

Kansas City, Missouri, United States, 64111

Actively Recruiting

13

Investigational Site 046

Kansas City, Missouri, United States, 66160

Actively Recruiting

14

Investigational Site 015

New York, New York, United States, 10016

Actively Recruiting

15

Investigational Site 022

New York, New York, United States, 10032

Actively Recruiting

16

Investigational Site 009

Cincinnati, Ohio, United States, 45219

Actively Recruiting

17

Investigational Site 003

Cleveland, Ohio, United States, 44195

Actively Recruiting

18

Investigational Site 005

Austin, Texas, United States, 78705

Actively Recruiting

19

Investigational Site 013

Houston, Texas, United States, 77030

Actively Recruiting

20

Investigational Site 042

Burlington, Vermont, United States, 05401

Actively Recruiting

21

Investigational Site 006

Charlottesville, Virginia, United States, 22903

Actively Recruiting

22

Investigational Site 023

Norfolk, Virginia, United States, 23507

Actively Recruiting

23

Investigational Site 045

Richmond, Virginia, United States, 23284

Actively Recruiting

24

Investigational Site 027

Ottawa, Ontario, Canada, K1N 6N5

Actively Recruiting

25

Investigational Site 028

Montpellier, France, 34090

Actively Recruiting

26

Investigational Site 021

Paris, France, 75013

Actively Recruiting

27

Investigational Site 036

Pessac, France, 33600

Actively Recruiting

28

Investigational Site 019

Poitiers, France, 86000

Actively Recruiting

29

Investigational Site 037

Toulouse, France, 31400

Actively Recruiting

30

Investigational Site 038

Toulouse, France, 31400

Actively Recruiting

31

Investigational Site 052

Dresden, Germany, 01069

Actively Recruiting

32

Investigational Site 034

Athens, Greece, 115 28

Actively Recruiting

33

Investigational Site 039

Nea Ionia, Greece, 142 33

Actively Recruiting

34

Investigational Site 032

Voula, Greece, 166 73

Actively Recruiting

35

Investigational Site 029

Genoa, Italy, 16132

Actively Recruiting

36

Investigational Site 040

Genoa, Italy, 16147

Actively Recruiting

37

Investigational Site 007

Milan, Italy, 20157

Actively Recruiting

38

Investigational Site 051

Padua, Italy, 35143

Actively Recruiting

39

Investigational Site 033

Udine, Italy, 33100

Actively Recruiting

40

Investigational Site 041

Varese, Italy, 21100

Actively Recruiting

41

Investigational Site 051

Warsaw, Poland, 02-097

Actively Recruiting

42

Investigational Site 031

Warsaw, Poland, 02-507

Actively Recruiting

43

Investigational Site 025

Belgrade, Serbia, 11000

Actively Recruiting

44

Investigational Site 026

Belgrade, Serbia, 11040

Actively Recruiting

45

Investigational Site 048

Barcelona, Spain, 08017

Actively Recruiting

46

Investigational Site 010

Barcelona, Spain, 8035

Actively Recruiting

47

Investigational Site 024

Madrid, Spain, 28850

Actively Recruiting

48

Investigational Site 011

Murcia, Spain, 30120

Actively Recruiting

49

Investigational Site 020

London, United Kingdom, EC1A 7BE

Actively Recruiting

50

Investigational Site 047

London, United Kingdom, NW3 2QG

Actively Recruiting

51

Investigational Site 035

London, United Kingdom, SE1 7EH

Actively Recruiting

52

Investigational Site 017

Southampton, United Kingdom, SO17 1BJ

Actively Recruiting

Loading map...

Research Team

C

Clinical Project Manager

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

7

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis | DecenTrialz